Severely obese adults (18 years or older) have a significantly weaker immune response to the vaccine, compared with normal-weight people, new research shows. Professor Volkan Demirhan Yumuk of Istanbul University, Turkey, and colleagues conducted the study, which was presented this year at the European Congress on Obesity (ECO) in Maastricht, The Netherlands, from May 4 to 7. The study also found that severely obese individuals (BMI over 40kg/m2) who received the Pfizer/BioNTech BNT162b2 mRNA vaccine produced significantly more antibodies than those who received the CoronaVac (inactivated SARS-CoV-2) vaccine, suggesting that the Pfizer/BioNTech vaccine may be A better choice for this vulnerable population. Obesity is a disease that complicates the course of COVID-19, and vaccine antibody responses may be affected in obese adults. Influenza, hepatitis B and rabies vaccines have shown lower responses in obese people.
This article is reprinted from: https://www.solidot.org/story?sid=71495
This site is for inclusion only, and the copyright belongs to the original author.